GSK PLC

GSK PLC’s analyst upgrades reveal why investors see steady growth: robust earnings, diverse portfolio, cost cuts, and a strong pipeline that outpaces peers like Pfizer and Novartis.

GSK PLC tops Q4 earnings, driven by specialty HIV and respiratory drugs, aims for £40B sales by 2031, and plans strategic acquisitions to grow.

GSK cuts up to 350 R&D jobs yet boosts investment, showing its focus on oncology, immunology and rare‑disease breakthroughs amid portfolio gains and regulatory wins.

GSK’s $2.5 bn acquisition of Rapt Therapeutics gives the pharma giant a Phase IIb anti‑IgE allergy therapy, boosting its portfolio, opening high‑growth markets, and positioning it for value‑based reimbursement success.

GSK’s AI‑driven R&D and Summit Therapeutics oncology partnership aim to offset $2.1 bn in patent‑expiry losses, targeting a $950 m NPV if approvals arrive by 2027.

GSK’s new approvals for Exdensur and Nucala unlock a $27.9 billion‑plus Asian biologic market, boosting revenue, payer value‑based deals, and patient access in Japan and China.

GSK sells its U.S. manufacturing plant to Samsung Biologics for $280 million, boosting Samsung’s first U.S. site, strengthening supply‑chain resilience, and funding GSK’s R&D while it cuts respiratory drug prices for better patient access.

GSK’s new drug Exdensur (depemokimab) gets UK approval, proving it reduces asthma and nasal‑polyp symptoms by targeting IL‑5Rα with a twice‑yearly shot.

GSK’s latest EU and US approvals—depemokimab, Nucala, Arexvy, Blujepa—show how pricing, reimbursement and supply‑chain agility drive commercial success in respiratory and infectious disease markets.

GSK reaffirms a £30bn U.S. expansion, prioritising drug development and manufacturing to tap high‑revenue markets amid new zero‑duty trade terms.